Bio-Gene Technology (ASX:BGT) Cash per Share: A$0.00 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Bio-Gene Technology Cash per Share?

Bio-Gene Technology ASX:BGT Cash per Share is A$0.00 as of Dec. 2025. The stock has 2 warning signs investors should review.

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Bio-Gene Technology's Cash per Share for the quarter that ended in Dec. 2025 was A$0.00.

Bio-Gene Technology  (ASX:BGT) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Bio-Gene Technology Cash per Share Related Terms

Bio-Gene Technology Cash per Share Historical Data

* Premium members only.

The historical data trend for Bio-Gene Technology's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio-Gene Technology Cash per Share Chart

Bio-Gene Technology Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Cash per Share
Get a 7-Day Free Trial 0.03 0.04 0.02 0.01 0.00

Bio-Gene Technology Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.01 0.01 0.00 0.00

Bio-Gene Technology Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Bio-Gene Technology's Cash per Share for the fiscal year that ended in Jun. 2025 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=1.138/266.42
=0.00

Bio-Gene Technology's Cash per Share for the quarter that ended in Dec. 2025 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=1.081/305.06
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash per Share →
What does a Cash per Share of A$0.00 mean?
Bio-Gene Technology (ASX:BGT) has a Cash per Share of A$0.00 as of Dec. 2025. Cash per share is the per-share value of a company's available cash. View historical data for Bio-Gene Technology and its competitors.
Is Bio-Gene Technology's Cash per Share too high?
Bio-Gene Technology's current Cash per Share is A$0.00.
How does Bio-Gene Technology's Cash per Share compare to VRTX and REGN?
Bio-Gene Technology's Cash per Share of A$0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash per Share for a Biotechnology company?
A good Cash per Share depends on the Biotechnology industry context. However, Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash per Share mean?
A high Cash per Share can signal that a stock is expensive relative to its fundamentals. Cash per share is the per-share value of a company's available cash. View historical data for Bio-Gene Technology and its competitors. Bio-Gene Technology's current Cash per Share is A$0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Gene Technology stock overvalued right now?
Bio-Gene Technology (ASX:BGT) has a current Cash per Share of A$0.00. The current Cash per Share is A$0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash per Share calculated?
Cash per Share is calculated from a company's financial statements. For Bio-Gene Technology (ASX:BGT), the current Cash per Share is A$0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bio-Gene Technology Business Description

Address 400 Collins Street, Level 6, Melbourne, VIC, AUS, 3000
Bio-Gene Technology Ltd is an Australian company developing novel bio-insecticides to address the challenges of insecticide resistance and toxicity. Its products are based on a naturally occurring class of compounds to overcome resistance to control pests with minimal impact on human health and the environment. Bio-Gene's products have multiple applications across public health, crop protection, grain storage, and consumer use. The company operates in one business segment, being the conduct of research and development activities in the discovery of novel insecticides.